Department of Medicine 1, Friedrich-Alexander University of Erlangen-Nürnberg, Germany.
Clin Pharmacol Ther. 2017 Oct;102(4):623-632. doi: 10.1002/cpt.793. Epub 2017 Aug 24.
Inflammatory bowel diseases (IBDs) are a lifelong condition of chronic, recurrent inflammation in the gut. The introduction of immunomodulators and biologic agents markedly improved the treatment of IBDs. Therefore, the use of biologics became an essential element in the rational therapy of IBDs. Various substances are currently evaluated in clinical trials, addressing different target structures and offering further approaches in the field of IBD. Regarding the growing number of treatment options, the need for prediction of therapy response became a necessity and is the subject of the present research.
炎症性肠病(IBD)是一种终生存在的慢性、复发性肠道炎症疾病。免疫调节剂和生物制剂的引入显著改善了 IBD 的治疗效果。因此,生物制剂的使用成为 IBD 合理治疗的重要组成部分。目前,各种物质正在临床试验中进行评估,针对不同的靶结构,并在 IBD 领域提供了进一步的治疗方法。鉴于治疗选择的数量不断增加,预测治疗反应的需求成为了必要,这也是本研究的主题。